Most-Downgraded StocksMost-DowngradedNYSE:EW Edwards Lifesciences (EW) Stock Price, News & Analysis $69.75 -0.78 (-1.11%) (As of 12:04 PM ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends About Edwards Lifesciences Stock (NYSE:EW) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Edwards Lifesciences alerts:Sign Up Key Stats Today's Range$69.60▼$70.5750-Day Range$64.54▼$72.0752-Week Range$58.93▼$96.12Volume1.06 million shsAverage Volume4.62 million shsMarket Capitalization$41.14 billionP/E Ratio10.06Dividend YieldN/APrice Target$77.25Consensus RatingHold Company OverviewEdwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names. The company also provides surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS name; INSPIRIS RESILLA aortic valve, which offers RESILIA tissue and VFit technology; KONECT RESILIA, a pre-assembled tissue valves conduit for complex combined procedures; and MITRIS RESILIA valve. In addition, it offers critical care solutions, including hemodynamic monitoring systems to measure a patient's heart function and fluid status in surgical and intensive care settings under the FloTrac, Acumen IQ sensors, ClearSight, Acumen IQ cuffs, and ForeSight names; HemoSphere, a monitoring platform that displays physiological information; and Acumen Hypotension Prediction Index software that alerts clinicians in advance of a patient developing dangerously low blood pressure. The company distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.Read More… Why I'm telling friends to avoid gold stocks (Ad)Back in November, gold made a tiny move of 1.6%. But according to my backtesting by using a special type of gold trade, I would have seen a 141% gain in just a week. It happened again in March. Gold nudged up 1.2%. This time? A 104% overnight gain. And in June? A 1% gold move turned into a 74% gain in two weeks. Granted, there would have been smaller wins and those that did not work out, but you see, there's a reason I'm telling all my friends to hold off from buying gold or regular gold stocks right now. There's a more lucrative way to play the gold market as we enter a new breakout period. It's all about catching what I call "Acceleration Cycles."And if you’d like to get your hands on this, here you go, the complete breakdown. Edwards Lifesciences Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks93rd Percentile Overall ScoreEW MarketRank™: Edwards Lifesciences scored higher than 93% of companies evaluated by MarketBeat, and ranked 102nd out of 975 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.2 / 5Analyst RatingHold Consensus RatingEdwards Lifesciences has received a consensus rating of Hold. The company's average rating score is 2.38, and is based on 10 buy ratings, 16 hold ratings, and no sell ratings.Amount of Analyst CoverageEdwards Lifesciences has been the subject of 16 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Edwards Lifesciences' stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings Growth-5.06% Earnings GrowthEarnings for Edwards Lifesciences are expected to decrease by -5.06% in the coming year, from $2.57 to $2.44 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Edwards Lifesciences is 10.10, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 123.07.Price to Earnings Ratio vs. SectorThe P/E ratio of Edwards Lifesciences is 10.10, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 85.71.Price to Earnings Growth RatioEdwards Lifesciences has a PEG Ratio of 4.01. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioEdwards Lifesciences has a P/B Ratio of 6.31. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Edwards Lifesciences' valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted1.18% of the float of Edwards Lifesciences has been sold short.Short Interest Ratio / Days to CoverEdwards Lifesciences has a short interest ratio ("days to cover") of 1.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Edwards Lifesciences has recently decreased by 10.78%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldEdwards Lifesciences does not currently pay a dividend.Dividend GrowthEdwards Lifesciences does not have a long track record of dividend growth. Sustainability and ESG4.0 / 5Environmental Score-0.95 Percentage of Shares Shorted1.18% of the float of Edwards Lifesciences has been sold short.Short Interest Ratio / Days to CoverEdwards Lifesciences has a short interest ratio ("days to cover") of 1.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Edwards Lifesciences has recently decreased by 10.78%, indicating that investor sentiment is improving significantly. News and Social Media2.4 / 5News Sentiment0.31 News SentimentEdwards Lifesciences has a news sentiment score of 0.31. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.87 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 87 news articles for Edwards Lifesciences this week, compared to 19 articles on an average week.Search InterestOnly 4 people have searched for EW on MarketBeat in the last 30 days. This is a decrease of -43% compared to the previous 30 days.MarketBeat Follows13 people have added Edwards Lifesciences to their MarketBeat watchlist in the last 30 days. This is an increase of 44% compared to the previous 30 days. Company Ownership2.5 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Edwards Lifesciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $2,657,000.00 in company stock.Percentage Held by InsidersOnly 1.27% of the stock of Edwards Lifesciences is held by insiders.Percentage Held by Institutions79.46% of the stock of Edwards Lifesciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Edwards Lifesciences' insider trading history. Receive EW Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Edwards Lifesciences and its competitors with MarketBeat's FREE daily newsletter. Email Address EW Stock News HeadlinesDonald E. Bobo, Jr. Sells 5,000 Shares of Edwards Lifesciences Co. (NYSE:EW) StockNovember 14, 2024 | insidertrades.comInsider Selling: Edwards Lifesciences Co. (NYSE:EW) Insider Sells 25,000 Shares of StockNovember 6, 2024 | insidertrades.comNew Year, New Opportunity! 2 AI Stocks Under $10 Ready to SoarAs we step into 2025, artificial intelligence (AI) stocks continue to dominate headlines, and now is the perfect moment to position yourself for the coming year’s potential. Our latest research has uncovered two must-buy AI stocks currently trading under $10/share – an affordable entry with promising growth potential. These stocks are flying under the radar, but it’s only a matter of time before they gain mainstream attention.December 3, 2024 | Darwin (Ad)Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Edwards ...December 3 at 6:01 AM | gurufocus.comEdwards Lifesciences Corp (EW) Faces Class Action Lawsuit Over Securities Fraud AllegationsDecember 3 at 6:01 AM | gurufocus.comLevi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Edwards Lifesciences Corporation(EW) ShareholdersDecember 3 at 5:45 AM | prnewswire.comBarclays Issues Positive Forecast for Edwards Lifesciences (NYSE:EW) Stock PriceDecember 3 at 2:14 AM | americanbankingnews.comEdwards Lifesciences Corp (EW) Faces Securities Class Action LawsuitDecember 2 at 8:21 PM | gurufocus.comSee More Headlines EW Stock Analysis - Frequently Asked Questions How have EW shares performed this year? Edwards Lifesciences' stock was trading at $76.25 at the beginning of the year. Since then, EW shares have decreased by 8.2% and is now trading at $69.96. View the best growth stocks for 2024 here. How were Edwards Lifesciences' earnings last quarter? Edwards Lifesciences Co. (NYSE:EW) released its quarterly earnings results on Thursday, October, 24th. The medical research company reported $0.67 earnings per share for the quarter, hitting the consensus estimate of $0.67. Edwards Lifesciences's quarterly revenue was up 8.9% compared to the same quarter last year. Read the conference call transcript. When did Edwards Lifesciences' stock split? Edwards Lifesciences shares split on the morning of Friday, May 29th 2020. The 3-1 split was announced on Thursday, May 7th 2020. The newly issued shares were distributed to shareholders after the closing bell on Monday, May 18th 2020. An investor that had 100 shares of stock prior to the split would have 300 shares after the split. Does Edwards Lifesciences have any subsidiaries? Edwards Lifesciences subsidiaries include CAS Medical Systems, Harpoon Medical, Valtech Cardio, CardiAQ Valve Technologies, BMEYE, Embrella Cardiovascular, Myocor, and more. Who are Edwards Lifesciences' major shareholders? Edwards Lifesciences' top institutional investors include Wellington Management Group LLP (5.35%), State Street Corp (4.45%), Geode Capital Management LLC (2.29%) and Fisher Asset Management LLC (1.54%). Insiders that own company stock include Larry L Wood, Jean-Luc M Lemercier, Bernard J Zovighian, Kieran Gallahue, Donald E Bobo Jr, Catherine M Szyman, Scott B Ullem, Daveen Chopra, Heisz Leslie Stone, Martha H Marsh, Daniel J Lippis, Robert WA Sellers, Michael A Mussallem and Huimin Wang. View institutional ownership trends. How do I buy shares of Edwards Lifesciences? Shares of EW stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Edwards Lifesciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that Edwards Lifesciences investors own include Comcast (CMCSA), Chevron (CVX), Bristol-Myers Squibb (BMY), Charles Schwab (SCHW), McKesson (MCK), Yum! Brands (YUM) and Toronto-Dominion Bank (TD). Company Calendar Last Earnings10/24/2024Today12/03/2024Fiscal Year End12/31/2024Next Earnings (Estimated)2/04/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry Surgical appliances & supplies Sub-IndustryHealth Care Equipment Current SymbolNYSE:EW CUSIP28176E10 CIK1099800 Webwww.edwards.com Phone(949) 250-2500Fax949-250-2525Employees19,800Year Founded1958Price Target and Rating Average Stock Price Target$77.25 High Stock Price Target$105.00 Low Stock Price Target$63.00 Potential Upside/Downside+9.5%Consensus RatingHold Rating Score (0-4)2.38 Research Coverage26 Analysts Profitability EPS (Most Recent Fiscal Year)$6.93 Trailing P/E Ratio10.18 Forward P/E Ratio27.44 P/E Growth4.01Net Income$1.40 billion Net Margins70.82% Pretax Margin29.55% Return on Equity20.76% Return on Assets15.27% Debt Debt-to-Equity Ratio0.06 Current Ratio3.46 Quick Ratio2.89 Sales & Book Value Annual Sales$6.00 billion Price / Sales6.93 Cash Flow$2.73 per share Price / Cash Flow25.82 Book Value$16.30 per share Price / Book4.33Miscellaneous Outstanding Shares589,800,000Free Float582,192,000Market Cap$41.60 billion OptionableOptionable Beta1.12 Social Links The Best High-Yield Dividend Stocks for 2024Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.Get This Free Report This page (NYSE:EW) was last updated on 12/3/2024 by MarketBeat.com Staff From Our PartnersTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredYour bank is lying to you.You might think you have your money in a high-yield savings account, but do you really? The national average A...MyBankTracker | SponsoredHow this >10-cent coin is going to outperform Bitcoin Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredIs NVDA a sell? Buy this stock instead before Dec 3After months of speculation that Nvidia was "cooling off..." and "running out of steam..." The company is m...Chaikin Analytics | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Edwards Lifesciences Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share Edwards Lifesciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.